ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 31.4% on Monday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares traded hands during trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Stock Performance
The firm’s 50 day moving average is GBX 10.72 and its 200-day moving average is GBX 5.88. The stock has a market capitalization of £37.20 million, a price-to-earnings ratio of -8.31 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- How to buy stock: A step-by-step guide for beginners
- Why Gold Loves Trump as Much as Trump Loves Gold
- Election Stocks: How Elections Affect the Stock Market
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
